I’m happy to say that I’m not addicted to e-mail. Or at least I don’t think I am.

However, I’ve come to realize that communicating through email is preferred to picking up the telephone by a fairly large margin. In fact, I actually prefer it as it lets me keep a written record of communication, not necessarily for legal purposes, but for organizational purposes.

During a typical day, I get so focused on the job at hand that if you want me to do something, you better send me an email. Why? Because in the process of verbally adding a …

I believe we will continue to find direction in the market with the news due out next week.

The Federal Budget is due out on May 12th, posed to reveal the typical boost from tax receipts. However, the governments stimulus package will lead to a $400 billion deficit for the year.

Wal-Mart is due to release earnings on May 13th, which I believe will uncover the true consumer sentiment. EPS for the retailer are forecast to be up 10% from a year ago. I think this data will confirm a shift in consumer spending from larger, brand-name stores to the discount stores. Later on in the week (May …

I started reading over the Schering-Plough (SGP: chart, web, Y!) 2007 financial report in an effort to do some more research.

Interestingly enough, I’m starting to rethink my position on Schering. SGP had really fallen out of favor with me since the whole Vytorin mess really blew up, and the stock price sunk to $13.83 per share for its 52 week lows.

After digesting some of the numbers though, I don’t think things look all that bad… at least not bad enough to justify the $18 share price.

Back in November of last year, Schering bought Organon BioSciences (OBS) for about $16.1 billion.  Effectively, that entire acquisition …